Latest Medtech News

Uscom Limited reported a 25% revenue decline in FY25 amid global geopolitical challenges but reinforced its commitment to growth through strategic partnerships and innovative medical technologies.

Navigator Global Investments delivered record financial results in FY25, driven by strong revenue growth and strategic expansion, while suspending dividends to fuel future growth. Key leadership changes mark a new chapter for the alternative asset manager.

ReNerve Limited’s innovative NervAlign® Nerve Cuff has secured approval for use across the US Department of Defense and Veterans Affairs healthcare systems, marking a major milestone for the Australian medtech company.

Pathkey.AI has teamed up with Armstrong Clinical to blend AI-driven trial predictions with expert clinical strategy, aiming to boost early-phase trial success and accelerate drug development in Australia and beyond.

Invex Therapeutics has appointed two new non-executive directors and joint company secretaries, signaling a refreshed governance structure alongside a change of company address.

Clever Culture Systems reports a cashflow positive quarter, expanding its pharmaceutical customer base and launching a new contact plate analysis module that promises to drive recurring revenues.

Hydrix Limited reports a robust quarter with $3.35 million in sales, a 7% revenue increase, and a strong international client base, while advancing US market ventures.

Cambium Bio has locked in a significant R&D tax rebate and forged three strategic partnerships, underpinning its Phase 3 clinical trials for its lead ophthalmology biologic. The company’s recent capital raise further strengthens its runway as it prepares for pivotal trial milestones.

Uscom Limited has struck a deal to sell its entire business to Singapore-based AXO Medtech VCC for $2.59 million, aiming to unlock capital for growth under new ownership. Shareholder approval is the next critical step before the transaction can proceed.

Hydrix Limited delays its FY25 financial statements due to a pending independent valuation of its Wavewise Analytics shareholding, triggering an automatic trading suspension from 1 October 2025.

Rewardle Holdings has cleared a major compliance hurdle by releasing its preliminary report, spotlighting its strategic investment in cardiac MedTech firm CloudHolter and ongoing B2B2C platform development.

Rewardle Holdings reported a modest revenue increase for FY25 but saw its loss more than double, driven by investments in AI-powered MedTech associate CloudHolter and expanded platform initiatives.